SHORTWAVE LIFE SCIENCES
PLC
("Shortwave" or "the
Company")
Shortwave Life Sciences Achieves Major Milestone: Positive
Pre-Clinical Results Drive Combination Drug for Anorexia Toward
Human Trials
London, 19 September 2024 -
Shortwave Life Sciences (AQSE: PSY), a pioneer in mental health
innovation, has achieved a significant breakthrough in its journey
to transform the treatment landscape of eating disorders. The
Company is thrilled to announce positive safety results from its
latest pre-clinical pharmacodynamics study, demonstrating the
safety of its proprietary psilocybin-based drug combination at
elevated doses.
In collaboration with Science in
Action, an expert pre-clinical GLP-certified lab in Israel, the
study tested the safety of buccal administration of Shortwave's
combination drug comprised of psilocybin and a beta
carboline.
The study involved three groups of
rats given varying doses of the combination drug (0.23ml, 0.5ml,
and 1ml), with results showing no adverse effects, weight changes,
or behavioral changes following the psychedelic effects. All
subjects remained healthy and unaffected during the trial, marking
a strong foundation for future clinical development.
Key
Highlights of the Study:
•
No adverse events or vital sign changes were reported across all
groups.
•
Safety profile confirmed for the psilocybin-based combination drug
at elevated doses.
•
Reaffirmation of Shortwave's buccal delivery platform's efficiency,
targeting mental health challenges including eating disorders and
anorexia nervosa.
CEO
Rivki Stern Youdkevich stated, "This
is a monumental step forward for Shortwave. Our relentless pursuit
of breakthrough mental health treatments comes with the
responsibility of ensuring safety at every stage. We are proud of
the positive outcomes from this rigorous pre-clinical trial,
further validating our patent-pending drug combination and buccal
delivery system. With this success, we are reaffirmed in our
approach to addressing the global mental health crisis."
This achievement comes on the heels of
the International PCT Examining Committee's recent acknowledgement
of Shortwave's patent claims for its novel, non-obvious, and
industrially applicable mucoadhesive buccal film. Designed for
rapid absorption and bypassing liver and gut degradation, the
platform holds transformative potential for patients facing
metabolic and psychiatric challenges.
This milestone continues to drive
Shortwave to the forefront of innovation, reinforcing the Company's
commitment to addressing unmet medical needs in mental health with
cutting-edge therapeutic approaches, in the field of eating
disorders.
As the Company gears up for human
trials, investors are encouraged to stay tuned for further
advancements that could reshape the mental health treatment
landscape.
About Shortwave Life
Sciences:
Shortwave Life Sciences is a developer of breakthrough
therapies addressing unmet medical needs in mental health. The
Company is committed to the advancement of innovative solutions
through drug development, with a mission to pioneer breakthrough
therapies that transform the landscape of mental health care. With
a team of dedicated experts and a commitment to innovation,
Shortwave Life Sciences is uniquely positioned to introduce and
develop solutions for the complex challenges of mental health
disorders worldwide.
The Directors of the Company accept
responsibility for the contents of this announcement.
For media inquiries, please contact:
Enquiries:
Company:
Rivki
Stern: +972 547621621
Peterhouse Capital
Limited:
Corporate
Adviser:
+ 44 (0) 20 7469 0930
Corporate
Broker:
+44 (0) 20 7220 9797